D.E. Shaw & Co
NGM

D.E. Shaw & Co’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

D.E. Shaw & Co’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-308,104
Closed -$265K – 4852
2023
Q4 		$265K Sell
308,104
-14,368
-4% -$12.6K ﹤0.01% 3790
2023
Q3 		$345K Sell
322,472
-32,418
-9% -$67.1K ﹤0.01% 3563
2023
Q2 		$919K Buy
354,890
+77,816
+28% +$278K ﹤0.01% 3147
2023
Q1 		$1.13M Buy
277,074
+154,118
+125% +$712K ﹤0.01% 3083
2022
Q4 		$617K Sell
122,956
-16,301
-12% -$102K ﹤0.01% 3737
2022
Q3 		$1.82M Sell
139,257
-21,608
-13% -$327K ﹤0.01% 3095
2022
Q2 		$2.06M Buy
160,865
+97,468
+154% +$1.35M ﹤0.01% 3041
2022
Q1 		$967K Buy
63,397
+3,366
+6% +$52.5K ﹤0.01% 3946
2021
Q4 		$1.06M Buy
60,031
+14,953
+33% +$287K ﹤0.01% 3883
2021
Q3 		$948K Sell
45,078
-60
-0.1% -$1.32K ﹤0.01% 3642
2021
Q2 		$890K Buy
45,138
+34,950
+343% +$818K ﹤0.01% 3636
2021
Q1 		$296K Buy
+10,188
New +$285K ﹤0.01% 3715

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's NGM Position: Q1 2024 in Review

D.E. Shaw & Co sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 308,104 shares — an estimated $265K sold.

D.E. Shaw & Co first reported a position in NGM in Q1 2021 and held it in 12 quarters. The position peaked at $2.06M in Q2 2022. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • D.E. Shaw & Co reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 308,104 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $265K.
  • D.E. Shaw & Co first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
  • D.E. Shaw & Co's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $2.06M in Q2 2022.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.